Why Did Option Care Health (Nasdaq:OPCH) Stock Surge 33% on the McKesson Deal?

Option Care Health Inc. (Nasdaq:OPCH) closed up about 33%, near $31, after agreeing to be acquired by McKesson and Clayton, Dubilier & Rice for $32.05 a share in cash. The offer values the equity at about $5.8 billion and represents a premium of roughly 37% to Monday’s closing price.

How the deal is structured

The transaction is split between two buyers. CD&R would own 51% of the company and McKesson 49%, and there is a path for McKesson to buy the remaining stake at a later date. Option Care Health will continue to operate as a separate company under its current management team. Closing is targeted for the first half of 2027, subject to the usual shareholder and regulatory approvals.

The arrangement combines a financial sponsor with a strategic partner, a structure used when one party offers capital and operating experience and the other brings industry relationships. By leaving the business independent and retaining its management, the buyers signal that they intend to keep the existing operating model rather than integrate Option Care into a larger group.

The market’s reaction

Shares closed near $31, about 3% below the $32.05 offer price. A gap of that kind is normal in announced deals and reflects the time to completion and the risk that approvals or financing could prove troublesome. With closing expected in the first half of 2027, investors are accepting a small discount in return for the near-certainty of a cash payout.

Trading volume was exceptional: about 65 million shares changed hands, compared with an average near 2 million, a multiple of more than 30 times. This kind of turnover usually reflects a rapid change in the shareholder base, with long-term holders selling into the premium and merger-arbitrage funds buying shares to hold until closing.

Why after-hours trading was quiet

Extended-hours activity was subdued because the stock had already moved to the deal price during the regular session. Once a takeover is announced and a cash price is set, the shares are anchored to that value, and movement tends to be limited to small changes in the spread. Further price action will depend on the possibility of a competing bid, which is generally low for deals structured with two well-capitalised buyers, and on regulatory developments.

Considerations for shareholders

A 37% premium is a substantial payout in a deal of this size. Shareholders will weigh it against the company’s standalone prospects and against recent trading ranges. Boards typically review the fairness of the price and the strength of the financing commitments, and shareholders will have the chance to vote. The first-half 2027 timeline leaves a long period in which developments in the market or in regulation could affect the spread.

The involvement of McKesson, a major distributor in the healthcare supply chain, may attract close regulatory review, although its stake is shared and the business will remain separate. How regulators view the arrangement will be one of the main variables to monitor.

What to watch next

The next milestones include the filing of merger documents, the date of the shareholder vote, any regulatory filings, and the movement of the spread between the share price and $32.05. A narrowing spread would show growing confidence that the transaction will close on schedule